PCDHB12: A Potential Drug Target and Biomarker for Prostate and Lung Cancer

Target Name: PCDHB12

NCBI ID: G56124

PCDHB12

PCDHB12: A Potential Drug Target and Biomarker for Prostate and Lung Cancer

Prostate and lung cancer are two of the leading causes of cancer-related deaths worldwide. The majority of these cancers are derived from epithelial cells, which have a high potential for metastasis due to their simple cell structure and frequent invasiveness. The identification of potential drug targets and biomarkers for these cancers has the potential to improve treatment outcomes and reduce the risk of recurrence. One such potential drug target and biomarker is PCDHB12, a gene that has been identified as a potential therapeutic target in both prostate and lung cancer.

PCDHB12: Structure and Function

PCDHB12 is a gene that encodes the protocadherin beta-12 subunit of the cadherin family. The cadherin family is a transmembrane protein that plays a central role in cell-cell adhesion and tissue organization. The beta-12 subunit of cadherin is a 21-kDa protein that is involved in the formation of tight junctions, which are a type of cell-cell adhesion that is critical for tissue structure and function.

In cancer, abnormalities in the cadherin family have been implicated in the development and progression of many types of cancer, including prostate and lung cancer. For example, studies have shown that loss of the cadherin gene is a common event in both prostate and lung cancer, and that these mutations can lead to the development of aggressive and recurrent cancers.

In addition to its role in cadherin function, PCDHB12 has also been shown to play a role in cell signaling and metabolism. For example, PCDHB12 has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis, and has been shown to play a role in the development of cancer-induced stem cells.

PCDHB12 as a Drug Target

The identification of PCDHB12 as a potential drug target is based on several factors. First, the beta-12 subunit of cadherin is unique in that it is not expressed in many tissues, which may reduce its potential as a drug target. Second, the beta-12 subunit of cadherin has been shown to play a role in several cellular processes that are relevant to cancer development, including cell signaling, adhesion, and angiogenesis. Finally, the beta-12 subunit of cadherin has been shown to be involved in the development of cancer-induced stem cells, which may make it an attractive target for drugs that are designed to promote cancer cell proliferation.

In addition to its potential as a drug target, PCDHB12 has also been shown to be a potential biomarker for prostate and lung cancer. For example, studies have shown that PCDHB12 levels are elevated in prostate and lung cancer, and that these levels can be used as a biomarker for these cancers. In addition, some studies have shown that PCDHB12 is expressed in primary prostate and lung cancer cells, which may suggest that it is a potential target for these cancers.

PCDHB12 as a Biomarker

PCDHB12 has also been shown to be a potential biomarker for prostate and lung cancer. In these cancers, PCDHB12 levels are often elevated, and studies have shown that these levels can be used as a biomarker for these cancers. For example, some studies have shown that PCDHB12 levels are elevated in prostate and lung cancer samples, and that these levels can be used as a biomarker for these cancers. In addition, some studies have shown that PCDHB12 is expressed in primary prostate and lung cancer cells, which may suggest that it is a potential target for these cancers.

PCDHB12 has also been shown to have potential clinical applications as a biomarker. For example, some studies have shown that PC

Protein Name: Protocadherin Beta 12

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHB12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHB12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets